Is Pure, High Dose, CBD Ready for the Prescription Pad?

Most CBD products leave clinicians and patients guessing: unclear labels, inconsistent dosing, and the lingering worry of THC exposure. I’m Dr. Casey Grover, and as an addiction medicine physician I came into this conversation skeptical because I treat cannabis use disorder and I’ve seen how “cannabis-adjacent” products can go sideways in real life. Then I sat down with Pulak Sharma, founder and CEO of Kazmira Therapeutics, and Dr. Marwaha, an internal medicine physician, to dig into what changes when CBD is treated like a true medical therapy rather than a supplement.

We talk about what “prescription-grade” CBD actually means, including 503A compounding standards, a vertically integrated process, and why THC-free purity matters for prescribing, drug testing concerns, and patient safety. Dr. Marwaha shares how he’s using high-dose pure cannabidiol as an adjunct for generalized anxiety and chronic pain, especially in older adults who can’t tolerate NSAIDs or who become confused or sedated on typical options like gabapentin or muscle relaxers. We also get practical about what to monitor: medication interactions, liver function tests, and the real-world side effects he sees most often, like drowsiness and nausea.

We don’t dodge the evidence gaps. Instead, we discuss how structured outcomes tracking (think GAD-7 and PHQ-9) could build credible data around reduced reliance on benzodiazepines, opioids, and other higher-risk meds, and how telemedicine may expand access while keeping protocols consistent. We even explore what’s next, from nanoemulsion tech for faster onset to endometriosis pain and veterinary use where THC can be toxic to pets.

Subscribe, share this with a skeptical friend, and leave a review so more people can find the show.

To contact Dr. Grover: ammadeeasy@fastmail.com

To learn more about Kazmira's work: https://www.kazmiratx.com/